Johnson & Johnson (NYSE:JNJ) Shares Bought by Coastwise Capital Group LLC

Coastwise Capital Group LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 36.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,625 shares of the company's stock after buying an additional 2,295 shares during the quarter. Johnson & Johnson makes up about 1.2% of Coastwise Capital Group LLC's portfolio, making the stock its 21st biggest position. Coastwise Capital Group LLC's holdings in Johnson & Johnson were worth $1,430,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in JNJ. Souders Financial Advisors boosted its holdings in shares of Johnson & Johnson by 34.9% in the first quarter. Souders Financial Advisors now owns 3,065 shares of the company's stock valued at $508,000 after purchasing an additional 793 shares during the period. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Johnson & Johnson by 4.2% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 185,977 shares of the company's stock worth $30,843,000 after buying an additional 7,462 shares during the period. J.W. Cole Advisors Inc. grew its position in shares of Johnson & Johnson by 76.2% during the 1st quarter. J.W. Cole Advisors Inc. now owns 111,022 shares of the company's stock worth $18,412,000 after buying an additional 48,017 shares in the last quarter. Eagle Bay Advisors LLC raised its holdings in shares of Johnson & Johnson by 2.6% in the first quarter. Eagle Bay Advisors LLC now owns 4,754 shares of the company's stock valued at $788,000 after acquiring an additional 120 shares in the last quarter. Finally, Signet Investment Advisory Group Inc. lifted its stake in Johnson & Johnson by 7.7% in the first quarter. Signet Investment Advisory Group Inc. now owns 28,752 shares of the company's stock worth $4,768,000 after acquiring an additional 2,063 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded up $0.67 during mid-day trading on Friday, reaching $163.65. The stock had a trading volume of 9,764,459 shares, compared to its average volume of 8,141,137. The business's fifty day moving average is $154.29 and its 200-day moving average is $155.05. The firm has a market cap of $393.75 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 2.08 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm's revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.82 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.18%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on JNJ shares. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Guggenheim lifted their price target on Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a report on Thursday. Royal Bank Of Canada lifted their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday. Finally, Bank of America increased their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday. Eleven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $172.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.